Evidence map›Paper›PMID 11495585›Full record

ArticleJournal of medicinal chemistry2001

Fluorosulfonyl- and bis-(beta-chloroethyl)amino-phenylamino functionalized pyrazolo[4,3-e]1,2,4-triazolo[1,5-c]pyrimidine derivatives: irreversible antagonists at the human A3 adenosine receptor and molecular modeling studies.

P G Baraldi, B Cacciari, S Moro, R Romagnoli, Ji Xd, K A Jacobson, S Gessi, P A Borea, G Spalluto

Abstract read
In one paragraph

Article in Journal of medicinal chemistry, 2001. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.

0numbers the graph read from it
0cells of the map it votes in
13citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

13 citing papers in PubMed.

  1. Review
  2. Review
  3. Conjugable AEuropean journal of medicinal chemistry · 2020
    Article
  4. Chemical Probes for the Adenosine Receptors.Pharmaceuticals (Basel, Switzerland) · 2019
    Review
  5. Article
  6. An Affinity-Based Probe for the Human Adenosine AJournal of medicinal chemistry · 2018
    Article
  7. AMedicinal research reviews · 2018
    Review
  8. Article
  9. Article
  10. Article
  11. Review
  12. Review
  13. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

P G BaraldiDipartimento di Scienze Farmaceutiche, Università degli Studi di Ferrara, Via Fossato di Mortara 17-19, I-44100 Ferrara, Italy. pgb@dns.unife.it
B Cacciari
S Moro
R Romagnoli
Ji Xd
K A Jacobson
S Gessi
P A Borea
G Spalluto

Funding

Development Of Drugs Acting At Adenosine ReceptorsZIADK031117 · NIDDK · NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES · PI JACOBSON, KENNETH ALAN · 2009 to 2025
$10.4M
Intramural NIH HHS ZIA DK031117
6 · The paper itself

Abstract

A series of pyrazolotriazolopyrimidines was previously reported to be highly potent and selective human A(3) adenosine receptor antagonists (Baraldi et al. J. Med. Chem. 2000, 43, 4768-4780). A derivative having a methyl group at the N(8) pyrazole combined with a 4-methoxyphenylcarbamoyl moiety at N(5) position, displayed a K(i) value at the hA(3) receptor of 0.2 nM. We now describe chemically reactive derivatives which act as irreversible inhibitors of this receptor. Electrophilic groups, specifically sulfonyl fluoride and nitrogen mustard (bis-(beta-chloroethyl)amino) moieties, have been incorporated at the 4-position of the aryl urea group. Membranes containing the recombinant hA(3) receptor were preincubated with the compounds and washed exhaustively. The loss of ability to bind radioligand following this treatment indicated irreversible binding. The most potent compound in irreversibly binding to the receptor was 14, which contained a sulfonyl fluoride moiety and a propyl group at the N(8) pyrazole nitrogen. The bis-(beta-chloroethyl)amino derivatives displayed a much smaller degree of irreversible binding than the sulfonyl fluoride derivatives. A computer-generated model of the human A(3) receptor was built and analyzed to help interpret these results. The model of the A(3) transmembrane region was derived using primary sequence comparison, secondary structure predictions, and three-dimensional homology building, using the recently published crystal structure of rhodopsin as a template. According to our model, sulfonyl fluoride derivatives could dock within the hypothetical TM binding domain, adopting two different energetically favorable conformations. We have identified two amino acids, Ser247 and Cys251, both in TM6, as potential nucleophilic partners of the irreversible binding to the receptor.

Indexed as

Purinergic P1 Receptor AntagonistsAniline CompoundsAnimalsBinding, CompetitiveCell LineCricetinaeHeterocyclic Compounds, 3-RingHumansModels, MolecularPhenylurea CompoundsPyrimidinesRadioligand AssayReceptor, Adenosine A3Receptors, Purinergic P1Recombinant ProteinsStructure-Activity Relationship5-(((4-fluorosulfonylphenyl)amino)carbonyl)amino-8-n-propyl-2-(2-furyl)pyrazolol(4,3-e)1,2,4-triazolo(1,5-c)pyrimidineAniline CompoundsHeterocyclic Compounds, 3-RingPhenylurea CompoundsPurinergic P1 Receptor AntagonistsPyrimidinesReceptor, Adenosine A3Receptors, Purinergic P1Recombinant Proteins

Identifiers

PMID11495585
PMCPMC12445420

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.